2. Search Result
Search Result
Results for "

Irinotecan

" in MedChemExpress (MCE) Product Catalog:

53

Inhibitors & Agonists

1

Biochemical Assay Reagents

1

Peptides

5

Natural
Products

8

Isotope-Labeled Compounds

2

Oligonucleotides

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-13704
    SN-38
    65+ Cited Publications

    7-Ethyl-10-hydroxycamptothecin

    		 Drug Metabolite Topoisomerase ADC Payload Autophagy Infection Cancer
    SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 can bind to RPL15. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .
    SN-38
  • HY-16562
    Irinotecan
    Maximum Cited Publications
    75 Publications Verification

    (+)-Irinotecan; CPT-11; VAL-413free base

    		 Topoisomerase Autophagy Neurological Disease Cancer
    Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan
  • HY-16562A
    Irinotecan hydrochloride
    70+ Cited Publications

    (+)-Irinotecan hydrochloride; CPT-11 hydrochloride; VAL-413

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan hydrochloride
  • HY-16568
    Irinotecan hydrochloride trihydrate
    Maximum Cited Publications
    75 Publications Verification

    (+)-Irinotecan hydrochloride trihydrate; CPT-11 hydrochloride trihydrate

    		 Topoisomerase Autophagy Cancer
    Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
    Irinotecan hydrochloride trihydrate
  • HY-126373
    SN-38 glucuronide

    SN-38G

    		 Drug Metabolite Cancer
    SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .
    SN-38 glucuronide
  • HY-13704S
    SN-38-d3

    NK012-d3

    		 Topoisomerase ADC Payload Autophagy Cancer
    SN-38-d3 is the deuterium labeled SN-38. SN-38 (NK012) is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 (NK012) inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively .
    SN-38-d3
  • HY-113283
    Homogentisic acid

    		Amyloid-β Natriuretic Peptide Receptor (NPR) α-synuclein Transthyretin (TTR) Claudin Neurological Disease Metabolic Disease Cancer
    Homogentisic acid is an orally active, blood-brain barrier-permeable amyloidogenic compound that functions as both an amyloid component and a pigment precursor. Accumulation of homogentisic acid downregulates tight junction proteins (such as claudin-5, occludin, ZO-1) and impairs blood-brain barrier integrity. Homogentisic acid and its oxidation product benzoquinone acetic acid not only induce the aggregation and fibrosis of multiple proteins (such as Aβ1-42, α-synuclein, SAA, Transthyretin (TTR), atrial natriuretic peptide), but also trigger oxidative stress, damage to the Wnt/β-catenin pathway, and neurotoxicity, leading to ochronosis pigment deposition and synaptic dysfunction. At specific concentrations, homogentisic acid exerts no cytotoxicity or genotoxicity on human peripheral blood lymphocytes, and even counteracts the genotoxicity induced by Irinotecan (HY-16562). Homogentisic acid serves as an important tool molecule for investigating the mechanisms of diseases including ochronosis, secondary amyloidosis, Alzheimer's disease, and colorectal cancer .
    Homogentisic acid
  • HY-153013
    SN38-COOH

    		Drug-Linker Conjugates for ADC Cancer
    SN38-COOH is used for the synthesis of antibody-drug conjugates (ADCs). SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis .
    SN38-COOH
  • HY-12758
    YHO-13351

    		BCRP Cancer
    YHO-13351 is an orally active ABCG2 inhibitor . YHO-13351 modulates the function of ABCG2, blocks BCRP-mediated compound efflux, downregulates the expression of breast cancer resistance protein at the post-transcriptional level, and reverses ABCG2-associated tolerance. YHO-13351 restores the toxicity of SN-38 to SN-38-resistant cancer cells and sensitizes cancer cells to Irinotecan. YHO-13351 is a water-soluble prodrug that is rapidly converted to YHO-13177 (HY-12757) in mice. YHO-13351 prolongs the median survival time of mice bearing cancer cell xenografts when combined with IMMU-132. YHO-13351 extends the survival time of tumor-bearing mice and inhibits the growth of xenograft tumors when combined with Irinotecan. YHO-13351 can be used for the research of breast cancer, gastric cancer, BCRP-mediated drug-resistant cancers, and cervical cancer .
    YHO-13351
  • HY-139909A
    CL2E-SN38 TFA
    1 Publications Verification

    		 Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38 TFA, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .
    CL2E-SN38 TFA
  • HY-136170
    MC-SN38
    2 Publications Verification

    		 Drug-Linker Conjugates for ADC Cancer
    MC-SN38 is a agent-linker conjugate composed of a potent microtubule-disrupting agent SN38 and a non-cleavable MC linker to make antibody agent conjugate (ADC). SN-38, an active metabolite of the Topoisomerase I inhibitor Irinotecan, inhibits DNA synthesis and causes frequent DNA single-strand breaks .
    MC-SN38
  • HY-13704R
    SN-38 (Standard)

    7-Ethyl-10-hydroxycamptothecin (Standard)

    		 Drug Metabolite Reference Standards Topoisomerase ADC Payload Autophagy Cancer
    SN-38 (Standard) is the analytical standard of SN-38. This product is intended for research and analytical applications. SN-38 is an active metabolite of the Topoisomerase I inhibitor Irinotecan. SN-38 inhibits DNA and RNA synthesis with IC50s of 0.077 and 1.3 μM, respectively. SN-38 is a payload of sacituzumab govitecan (HY -132254) .
    SN-38 (Standard)
  • HY-12757
    YHO-13177
    2 Publications Verification

    		 BCRP Cancer
    YHO-13177, a acrylonitrile derivative, is an orally active, potent and specific inhibitor of breast cancer resistance protein (BCRP) and ABCG2 with an IC50 value of 10 nM. YHO-13177 potentiates the cytotoxicity of SN-38 in HCT116 and A549 cells that express BCRP. YHO-13177 combined with Irinotecan (HY-16562) significantly suppresses the tumor growth in an HCT116/BCRP xenograft model .
    YHO-13177
  • HY-145396
    PLGA12000-PEG2000-NH2

    		Biochemical Assay Reagents Cancer
    PLGA-PEG-NH2 is a material to synthesis nanomicelles. PLGA-PEG-NH2 nanomicelle is an efficient delivery system of Irinotecan for targeted colorectal cancer and hepatocellular carcinoma .
    PLGA12000-PEG2000-NH2
  • HY-16562S1
    Irinotecan-d10 hydrochloride

    		Isotope-Labeled Compounds Topoisomerase Autophagy Cancer
    Irinotecan-d10 (hydrochloride) is the deuterium labeled Irinotecan. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan-d10 hydrochloride
  • HY-W012985
    Methyl pyruvate

    		ATP Synthase Apoptosis Metabolic Disease Cancer
    Methyl pyruvate is a methyl ester derivative of pyruvic acid. Methyl pyruvate induces insulin release and membrane depolarization. Methyl pyruvate rescues proteasome damage and nuclear localization of TdP-43 caused by overexpression of σ1RE102Q by enhancing ATP synthesis. Methyl pyruvate selectively protects normal lung fibroblasts from cell death induced by Irinotecan (HY-16562). Methyl pyruvate promotes apoptosis and necrosis in cancer cells and downregulates angiogenesis and cell cycle pathways. Methyl pyruvate is an effective substrate for dihydrodihydrogen dehydrogenase.
    Methyl pyruvate
  • HY-146269
    11-Desethyl Irinotecan

    		Drug Metabolite Cancer
    11-Desethyl Irinotecan is a camptothecin (CPT) analog and one of the metabolites of irinotecan. It is promising for cancer research .
    11-Desethyl Irinotecan
  • HY-100620
    RPR121056

    APC

    		 Topoisomerase Cholinesterase (ChE) Cancer
    RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE .
    RPR121056
  • HY-173243A
    Val-Ala-PAB-SN38 TFA

    		Drug-Linker Conjugates for ADC Cancer
    Val-Ala-PAB-SN38 TFA is a drug-linker conjugate for ADC, composed of ADC linker Val-Ala-PAB (HY-125933) and SN38 (HY-13704), which is the active metabolite of the Topoisomerase I inhibitor Irinotecan (HY-16562) .
    Val-Ala-PAB-SN38 TFA
  • HY-155181
    CES2-IN-1

    		Carboxylesterase (CES) Cancer
    CES2-IN-1 (Compound 24) is a reversible and selective CES2 inhibitor (IC50: 6.72 μM for human CES2). CES2-IN-1 reduces the level of CES2 in living cells. CES2-IN-1 is effective against Irinotecan (HY-16562)-induced delayed diarrhea and DSS-induced ulcerative colitis .
    CES2-IN-1
  • HY-126373S1
    SN-38 glucuronide-13C6

    SN-38G-13C6

    		 Isotope-Labeled Compounds Others
    SN-38 glucuronide- 13C6 is the 13C labeled SN-38 glucuronide (HY-126373) . SN-38 glucuronide is an inactive metabolite of the cancer agent Irinotecan. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .
    SN-38 glucuronide-13C6
  • HY-139909
    CL2E-SN38

    		Drug-Linker Conjugates for ADC Cancer
    CL2E-SN-38, a highly releasable and structurally stable antibody-SN-38-conjugate, is a part of the antibody drug conjugate (ADC). SN-38, the active metabolite of Irinotecan from camptothecins, is an Topoisomerase I inhibitor .
    CL2E-SN38
  • HY-P10783
    BGC0222

    		Peptide-Drug Conjugates (PDCs) Integrin Cancer
    BGC0222 is a novel prodrug of Irinotecan (HY-16562). BGC0222, as a PEG-cRGD-conjugated Irinotecan (HY-16562) derivative, could slowly and steadily release Irinotecan (HY-16562). BGC0222 binds to αVβ3 with IC50 values of 4.25 μM (αVβ3) and 58.7 μM (αVβ5). BGC0222 possesses the property of inducing neovascularization. BGC0222 exhibits good antiproliferation activity in many tumors .
    BGC0222
  • HY-173243
    Val-Ala-PAB-SN38

    		Drug-Linker Conjugates for ADC Cancer
    Val-Ala-PAB-SN38 is a drug-linker conjugate for ADC, composed of ADC linker Val-Ala-PAB (HY-125933) and SN38 (HY-13704), which is the active metabolite of the Topoisomerase I inhibitor Irinotecan (HY-16562) .
    Val-Ala-PAB-SN38
  • HY-16568R
    Irinotecan hydrochloride trihydrate (Standard)

    (+)-Irinotecan hydrochloride trihydrate (Standard); CPT-11 hydrochloride trihydrate (Standard)

    		 Reference Standards Topoisomerase Autophagy Cancer
    Irinotecan (hydrochloride trihydrate) (Standard) is the analytical standard of Irinotecan (hydrochloride trihydrate). This product is intended for research and analytical applications. Irinotecan hydrochloride trihydrate ((+)-Irinotecan hydrochloride trihydrate) is a topoisomerase I inhibitor with antitumor activity .
    Irinotecan hydrochloride trihydrate (Standard)
  • HY-16562AR
    Irinotecan hydrochloride (Standard)

    (+)-Irinotecan hydrochloride (Standard); CPT-11 hydrochloride (Standard); VAL-413 (Standard)

    		 Reference Standards Topoisomerase Autophagy Cancer
    Irinotecan (hydrochloride) (Standard) is the analytical standard of Irinotecan (hydrochloride). This product is intended for research and analytical applications. Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan hydrochloride (Standard)
  • HY-174989
    ATM-IN-2

    		ATM/ATR Apoptosis Cancer
    ATM-IN-2 is a selective and orally active ATM inhibitor with an IC50 of 4 nM. ATM-IN-2 exhibits excellent kinase selectivity (>700-fold over PIKK family members). ATM-IN-2 exerts its anti-tumor effect by inhibiting ATM phosphorylation and the downstream signaling pathways (p53, H2AX), and promotes cell apoptosis. ATM-IN-2 can be used for the study of chemosensitizer candidate such as colon cancer .
    ATM-IN-2
  • HY-16562R
    Irinotecan (Standard)

    (+)-Irinotecan (Standard); CPT-11 (Standard); VAL-413free base (Standard)

    		 Reference Standards Topoisomerase Autophagy Cancer
    Irinotecan (Standard) is the analytical standard of Irinotecan. This product is intended for research and analytical applications. Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan (Standard)
  • HY-16562S
    Irinotecan-d10

    (+)-Irinotecan-d10; CPT-11-d10; VAL-413-d10free base

    		 Topoisomerase Autophagy Cancer
    Irinotecan-d10 is a deuterium labeled Irinotecan ((+)-Irinotecan). Irinotecan ((+)-Irinotecan) is a topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex .
    Irinotecan-d10
  • HY-131174
    8-Ethyl Irinotecan

    		Biochemical Assay Reagents Others
    8-Ethyl Irinotecan (compound H) is a impurity of Irinotecan hydrochloride (HY-16562A) .
    8-Ethyl Irinotecan
  • HY-16562AS
    Irinotecan-d5 hydrochloride

    (+)-Irinotecan-d5 (hydrochloride; CPT-11-d5 hydrochloride; VAL-413-d5

    		 Autophagy Topoisomerase Isotope-Labeled Compounds Cancer
    Irinotecan-d5 hydrochloride is deuterated labeled Irinotecan hydrochloride (HY-16562A). Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Irinotecan-d5 hydrochloride
  • HY-Z11281
    Irinotecan impurity 52

    		Drug Intermediate Others
    Irinotecan impurity 52 is an impurity of Irinotecan (HY-16562).
    Irinotecan impurity 52
  • HY-17648
    MBL-II-141

    		BCRP Cancer
    MBL-II-141 is potent ABCG2 inhibitor with an IC50 of 0.11 μM. MBL-II-141 inhibits the transport function of ABCG2 in a non-competitive manner, preventing ABCG2 from pumping substrates (such as Irinotecan (HY-16562)) out of the cells, thereby increasing the accumulation of drugs within the cells. MBL-II-141 has no effect on ABCB1 (P-gp) and ABCC1 (MRP1) and has extremely low cytotoxicity (IG50 > 100 μM). MBL-II-141 can be used for the study of multidrug resistance (MDR) cancers .
    MBL-II-141
  • HY-124446
    Dibromsalicil

    		Carboxylesterase (CES) Metabolic Disease
    Dibromsalicil (Compound 31) is a carboxylesterase (CES) inhibitor with activity of 72.7 nM against hiCE (human intestinal carboxylesterase) and 53.5 nM against rCE (rabbit liver carboxylesterase). Dibromsalicil has almost no activity against hCE1 (human liver carboxylesterase) and cholinesterase .
    Dibromsalicil
  • HY-100620R
    RPR121056 (Standard)

    APC (Standard)

    		 Drug Metabolite Reference Standards Topoisomerase Cholinesterase (ChE) Cancer
    RPR121056 (Standard) is the analytical standard of RPR121056. This product is intended for research and analytical applications. RPR121056 (APC) is a metabolite of Irinotecan (CPT-11), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the treatment of colorectal cancer. Irinotecan also directly inhibits AChE[1].
    RPR121056 (Standard)
  • HY-164271
    10-Boc-SN-38

    		Topoisomerase Cancer
    10-Boc-SN-38 is a tert-butyloxycarbonyl (Boc)-protected form of SN-38 (HY-13704). SN-38 is the active metabolite of Irinotecan (HY-16562) .
    10-Boc-SN-38
  • HY-155228
    LK-44

    		Carboxylesterase (CES) Inflammation/Immunology
    hCES2A-IN-2 (Compound 44) is an orally active human carboxylesterase 2 (hCES2A) inhibitor (IC50: 5.02 μM). hCES2A-IN-2 improves Irinotecan (HY-16562)-induced delayed diarrhea .
    LK-44
  • HY-147388
    hiCE inhibitor-1

    		Cholinesterase (ChE) Metabolic Disease
    hiCE inhibitor-1, a sulfonamide derivative, is a selective human intestinal enzyme (hiCE) inhibitor with a Ki value of 53.3 nM. hiCE inhibitor-1 can be used to improve Irinotecan (HY-16562)-induced diarrhoea .
    hiCE inhibitor-1
  • HY-16472R
    Sulfacytine (Standard)

    		Reference Standards Antibiotic Bacterial Infection
    Irinotecan (hydrochloride) (Standard) is the analytical standard of Irinotecan (hydrochloride). This product is intended for research and analytical applications. Irinotecan hydrochloride ((+)-Irinotecan hydrochloride) is a topoisomerase I inhibitor mainly used to treat colon cancer and rectal cancer .
    Sulfacytine (Standard)
  • HY-146080
    Antitumor agent-61

    		Apoptosis Cancer
    Antitumor agent-61 (Compound 9b), Irinotecan (Ir) derivative, is a potential antitumor agent. Antitumor agent-61 displays potent activity with IC50s of 0.92, 1.39, 1.75, 2.20, 3.05 and 3.23 μM against five human cancer cells SK-OV-3, SK-OV-3/CDDP, U2OS, MCF-7, A549 and MG-63, respectively. Antitumor agent-61 induces SK-OV-3 cells apoptosis through mitochondrion pathways .
    Antitumor agent-61
  • HY-141436R
    Sucrosofate potassium (Standard)

    Sucrose octasulfate potassium (Standard)

    		 Biochemical Assay Reagents Reference Standards Cancer
    Sucrosofate (potassium) (Standard) is the analytical standard of Sucrosofate (potassium). This product is intended for research and analytical applications. Sucrosofate (Sucrose octasulfate) potassium is a sucrose acid that can be used to prepare liposomes to deliver Irinotecan (HY-16562). Irinotecan is an inhibitor of topoisomerase Topo I and is commonly used in colon and rectal cancer research. Sucrosofate nanoliposome preparation loaded with Irinotecan, also known as PEP02 or MM-398 .
    Sucrosofate potassium (Standard)
  • HY-132561S
    RPR121056-d3

    APC-d3

    		 Isotope-Labeled Compounds Topoisomerase Cholinesterase (ChE) Cancer
    RPR121056-d3 is the deuterium labeled RPR121056. RPR121056 is a metabolite of Irinotecan (HY-16562), which is generated by CYP3A4. Irinotecan (CPT-11) is an antineoplastic agent that inhibits topoisomerase type I, causing cell death, and is widely used in the study of colorectal cancer. Irinotecan also directly inhibits AChE .
    RPR121056-d3
  • HY-W653919
    SN-38 glucuronide-d3

    		Isotope-Labeled Compounds Drug Metabolite Cancer
    SN-38 glucuronide-d3 is deuterium labeled SN-38 glucuronide. SN-38 glucuronide is an inactive metabolite of the anticancer active molecule Irinotecan (HY-16562) and has toxic effects on the gastrointestinal tract. Irinotecan is a topoisomerase I inhibitor which can be used for researching colon and rectal cancer .
    SN-38 glucuronide-d3
  • HY-185371
    Irinotecan liposome

    Irinotecan hydrochlorid liposomee; Liposomal Irinotecan

    		 Liposome Topoisomerase Cancer
    Irinotecan liposome is a liposome-encapsulated form of Irinotecan hydrochlorid (HY-16562A) (a topoisomerase I inhibitor). Compared with Irinotecan, Irinotecan liposome enhances antitumor activity, reduces drug release rate, and avoids neutropenia.
    Irinotecan liposome
  • HY-173267
    CES2A-IN-2

    		Carboxylesterase (CES) Metabolic Disease Cancer
    CES2A-IN-2 (compound 14n) is an orally active, highly specific, irreversible and covalent CES2A inhibitor with an IC50 of 0.04 nM for human CES2A. CES2A-IN-2 covalently binds to CES2A by specifically targeting the catalytic serine residue (Ser-228). CES2A-IN-2 can significantly ameliorate Irinotecan-triggered gut toxicity (ITGT) without diminishing the anti-tumor effects of Irinotecan (HY-16562) in tumor-bearing mice .
    CES2A-IN-2
  • HY-145513
    CL2-MMT-SN38

    		Topoisomerase Cancer
    CL2-MMT-SN38 is a SN-38 derivative. SN-38, an anticancer agent, is an active metabolite of the Topoisomerase I inhibitor Irinotecan (CPT-11) .
    CL2-MMT-SN38
  • HY-168516
    FXR/CES2 modulator 1

    		FXR Others
    FXR/CES2 modulator 1 (compound LE-77) is a doul modulator that activates FXR and inhibits CES2. FXR/CES2 modulator 1 effectively mitigates the intestinal toxicity of irinotecan .
    FXR/CES2 modulator 1
  • HY-14871
    Tenifatecan

    SN2310

    		 Topoisomerase Cancer
    Tenifatecan (SN2310) is an injectable emulsion composed of vitamin E, a succinate derivative, as well as 7-ethyl-10-hydroxycamptothecin (SN-38, the active metabolite of irinotecan). Tenifatecan (SN2310) possesses anticancer activity .
    Tenifatecan
  • HY-155034
    Antitumor agent-102

    		Topoisomerase GLUT Cancer
    Antitumor agent-102 (compound 10) is a conjugate of Topoisomerase I inhibitor SN38 and glucose transporter inhibitor, targeting to colorectal cancer. Antitumor agent-102 induces higher concentrations of free SN38 in tumor tissues than Irinotecan (HY-16562) .
    Antitumor agent-102
  • HY-132545S
    RPR132595A-d3

    NPC-d3

    		 Isotope-Labeled Compounds Topoisomerase Cancer
    RPR132595A-d3 is the deuterium labeled RPR132595A. RPR132595A is an active metabolite of Irinotecan (CPT-11), which is generated by cytochrome P-450 3A4 (CYP3A4) and finally excreted through urine .
    RPR132595A-d3

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: